Unbundling the Value Chain: Business Models from Digital Infrastructure to Physical Scale

By examining ten distinct companies across tech, media, and traditional industries, we explore how different business models capture value, mediate supply, and navigate the structural realities of today's market.

The key to understanding this seemingly random assortment of assets—from frontier biotechnology to legacy regional retail malls and semiconductor testing equipment—is understanding the underlying business models. Markets tend to categorize companies by industry labels, but when we view them through the lens of the value chain, we see entirely different mechanisms for value capture. This is not a simple story of sector rotation; it is a structural evolution of unbundling and scale.

Digital Infrastructure and the Attention Intermediaries

At the bottom of the technology stack, companies providing critical tools often secure an asymmetric niche. FormFactor (FORM.US) is a perfect case study. As a provider of vital test and measurement technologies for integrated circuits, its stock has recently seen strong momentum. The company reported Q1 2026 revenue of USD 226.1 million, up 32.0% year-over-year. This means that regardless of who ultimately wins the chip wars, the arms dealers consistently profit. Similarly, AvePoint (AVPT.US) occupies a crucial node in data security and cloud governance. With Q1 2026 revenue growing 26% to USD 117.2 million, its market cap has risen accordingly. These B2B enablers don't interact with the consumer, yet their infrastructure nature grants them immense stickiness.

In stark contrast sits Trump Media & Technology Group (DJTWW.US). Aggregation Theory dictates that a platform empowers third parties, while an aggregator directly intermediates the end user. DJTWW is attempting to monopolize a very specific demographic's attention. Yet, the company recorded a massive GAAP net loss of USD 405.9 million on a mere USD 900,000 in revenue in Q1 2026, leading to extreme price volatility. Attention can indeed be converted into equity, but without a robust monetization loop, it remains a fragile business model.

The Scale and Integration of the Physical World

Many investors assume that pure digital businesses are the only future. This, though, is exactly backwards. In the physical realm, moats built on heavy assets and economies of scale remain profoundly deep. Macerich (MAC.US), a leading U.S. retail property operator, has seen its shares consolidate near recent lows. In May 2026, the company acquired the Annapolis Mall for USD 272 million. This reflects a counterintuitive trend: Gen Z is rediscovering the social utility of brick-and-mortar retail, bringing value back to irreplaceable physical spaces.

In the consumer goods sector, Coca-Cola Consolidated (COKE.US) and Hormel Foods (HRL.US) demonstrate the sheer efficiency of legacy supply chains. COKE, the largest Coca-Cola bottler in the U.S., delivered a 3% net sales growth and a gross profit of USD 717 million in Q2 2026, with its stock showing strong defensive resilience. Hormel posted net sales of USD 2.97 billion in Q2 2026, maintaining steady stock performance year-to-date. Alongside Ingredion (INGR.US), which supplies underlying ingredient solutions and has maintained a relatively stable market valuation, these companies aren't disrupting anything. Instead, they extract margins in highly mature markets through operational excellence and distribution scale.

The Binary Outcomes of Capital-Intensive Frontiers

Finally, we must look at companies operating on the capital-intensive frontiers, where outcomes are often binary. Ring Energy (REI.US) extracts oil and gas in the Permian Basin; alongside liquidity improvements, its stock has recently recovered. The company reduced its debt by USD 66 million in Q2 2026, a crucial balance sheet repair necessary for survival in heavy industries.

In the biopharmaceutical space, Coherus BioSciences (CHRS.US) and Kala Pharmaceuticals (KALA.US) battle immense R&D risks. KALA, focused on eye diseases, saw its shares recover post-earnings after delivering a Q1 2026 EPS that beat estimates by 30%, as it advances its Phase 2b trial for KPI-012. Conversely, Coherus, despite its focus on biosimilars, faces fierce industry competition, leaving its stock continually under pressure. These entities represent the ultimate risk-reward trade-off at the very edge of the value chain—they either create entirely new value or are ruthlessly discarded by the market.